1. Home
  2. INTA vs VERA Comparison

INTA vs VERA Comparison

Compare INTA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intapp Inc.

INTA

Intapp Inc.

HOLD

Current Price

$23.29

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$42.26

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTA
VERA
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.4B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INTA
VERA
Price
$23.29
$42.26
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$50.25
$76.60
AVG Volume (30 Days)
1.7M
967.8K
Earning Date
02-03-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$543,341,000.00
N/A
Revenue This Year
$15.66
N/A
Revenue Next Year
$13.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.84
N/A
52 Week Low
$20.76
$18.53
52 Week High
$77.74
$56.05

Technical Indicators

Market Signals
Indicator
INTA
VERA
Relative Strength Index (RSI) 19.23 44.21
Support Level $22.88 $41.46
Resistance Level $26.32 $44.96
Average True Range (ATR) 2.19 2.19
MACD -0.63 -0.27
Stochastic Oscillator 14.56 28.81

Price Performance

Historical Comparison
INTA
VERA

About INTA Intapp Inc.

Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: